These analyses showed that the variant c.21G>A (p.Ser7Ser) abolished a consensus binding site for the Early Growth Response (EGR2) transcription factor, while the two other examined variants were not predicted to affect the binding sites of any transcription factors known to be involved in breast cancer. This evidence concerns the gene EGR2 and breast carcinoma.